Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …

Background: Postmarketing research has explored the optimal application schedule of
imiquimod 5% cream for treatment of external anogenital warts. Objectives: We systemically …

Since 2006, three vaccines against infections and disease caused by human papillomavirus
(HPV) became available in Europe—in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in …

Long‐lasting cutaneous warts are a therapeutic challenge, especially widespread or
symptomatic recalcitrant warts in children. It can be speculated that natural immunity to these …

Human papillomaviruses (HPV) are non‐enveloped tumor viruses with a double stranded
DNA approximately 8 kilobases in length. The viral genome is enclosed by a spherical …

As clinicians, we face an epidemic of human papillomavirus (HPV) infections. These
infections usually present as common warts or as genital warts (condylomata acuminata) but …

Imiquimod (also known as R-837 and S-26308) is an imidazoquinoline immune response
modifier and is available in the US and several other countries for the treatment of external …

An association between human papillomavirus (HPV) infection and the development of
cervical cancer was initially suggested over 30 years ago, and today there is clear evidence …

Wart therapies involve methods of targeted lesion destruction, as well as selective
immunologic modification. While there are several therapeutic options, no treatment has …

External genital warts, also known as condylomata acuminata, are extremely common, with
between 500,000 to one million new cases diagnosed each year in the United States alone …